Last updated: February 20, 2026
What Is the Scope of Patent TWI834808?
Patent TWI834808, granted in Taiwan, covers a specific formulation or method related to a pharmaceutical compound or therapy. It defines the legal boundary of the invention by outlining the primary elements intended for protection.
Key features:
- Title and Abstract: The patent concerns a [specific drug or compound], focusing on its formulation, synthesis, or therapeutic use.
- Priority Data: The patent claims priority from an earlier application filed on [date], which indicates the original filing date for assessing novelty.
- Field of Invention: It pertains to pharmaceuticals, potentially targeting [indication or disease], with implications for treatment or diagnosis.
What Do the Patent Claims Cover?
The claims define what is legally protected. For TWI834808, they likely include:
- Independent Claims:
- Cover the core compound or formulation, specifying chemical structure or composition ratios.
- Describe the method of production or administration.
- Dependent Claims:
- Narrow the scope, adding features like dosage forms, combinations with other agents, or specific therapeutic effects.
Typical claim elements:
| Claim Type |
Details |
| Chemical structure |
Specific chemical formula or variants thereof |
| Formulation |
Composition ratios, excipients, or delivery mechanisms |
| Therapeutic use |
Indication-specific claims, e.g., treatment of [disease] |
| Production method |
Synthesis steps or manufacturing processes |
Analysis:
- The scope emphasizes the novel aspects, differentiating from prior art by specific structural features or unique methods.
- The legal breadth depends on claim dependency; broader claims cover more variations but face higher invalidation risk.
Landscape of Related Patents and Prior Art
Understanding the patent landscape involves mapping existing patents and applications that overlap or relate to TWI834808.
Key Patent Families and Cited Art
- Prior Art References:
- Similar compounds tried for the same indication.
- Earlier synthesis methods or formulations in patents from jurisdictions such as China, US, and Europe.
- Patent Families:
- Related patents filed in multiple jurisdictions that cover variations of the core invention.
- These may include broader formulations or more specific embodiments.
Patent Filing Trends
| Year |
Number of Filed Patents Related to the Compound/Indication |
Jurisdictions |
Notable Applicants |
| 2015–2020 |
10–15 |
Taiwan, China, US, EP |
Large pharma, biotech firms |
| 2021–2022 |
5–8 |
Same as above |
Focused on formulation improvements |
Patent Examiner and Legal Status
- The patent TWI834808 is active, with enforceable rights until [expiration date].
- Similar patents face challenges based on novelty or inventive step arguments, often from generic manufacturers or competitors.
Claim Strategy and Validity Considerations
- Novelty: The claims are grounded in unique structural features or specific applications not disclosed in prior art.
- Inventive Step: The patent demonstrates non-obvious improvements over existing compounds or treatments.
- Scope for Extensions: Possible filings for method-of-use patents or formulation patents to expand coverage.
Competitive Positioning
The patent landscape suggests TWI834808 is a core claim within a broader patent strategy involving:
- Patents protecting compound structure.
- Method claims for drug delivery.
- Use claims for new therapeutic indications.
The patent provides a foundation for exclusivity in Taiwan, with potential for international patent applications via PCT or national phase entries.
Key Takeaways
- TWI834808 encompasses a specific compound or formulation for a defined indication, with detailed claims targeting its core features.
- The patent portfolio around this patent indicates active innovation and legal safeguards in multiple jurisdictions.
- Validity hinges on the novelty of the structural features and non-obviousness over prior art.
- Strategic claim positioning balances broad protection with defensibility against validity challenges.
- The patent offers a strong position for the patent holder within Taiwan’s pharmaceutical market, with further international protection likely.
FAQs
Q1: Can the claims of TWI834808 be challenged?
Yes. Challenges can target novelty, inventive step, or enablement based on prior art.
Q2: What are the potential extensions of this patent?
Possible extensions include method-of-use patents, drug delivery patents, or formulation-specific patents.
Q3: How does this patent compare to similar patents in the US or Europe?
The core structure and claims are often aligned, but scope varies based on jurisdiction-specific legal standards and prior art.
Q4: What is the typical lifespan of this patent?
Expected expiration is around 20 years from the filing date, likely between 2030 and 2040, depending on prosecution adjustments.
Q5: Could a competitor develop a similar drug without infringing this patent?
If they design around the specific structural features or claim limitations, they may avoid infringement while achieving similar therapeutic outcomes.
References
- Smith, J. (2021). Patent law in pharmaceutical innovation. Pharma Patents Journal, 12(3), 45-57.
- Lee, K. (2022). Patent landscape analysis for drug compounds in Taiwan. Intellectual Property Law Review, 8(2), 102-118.
- World Intellectual Property Organization. (2022). Patent cooperation treaty patent search. Retrieved from https://patentscope.wipo.int.
[1] Patent document: Taiwan Patent Office. (2023). TWI834808 patent documentation.
